Key facts
- It has raised $47.1M; the latest was Early Stage VC in Oct 2025.
- Notable investors include F-Prime Capital, Eight Roads.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AlphaGen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for AlphaGen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AlphaGen Therapeutics
Developer and provider of radiopharmaceutical products intended to bring patients innovative radiotherapy solutions. The company's products include alpha nuclide radiopharmaceuticals as the core, with other drugs in early clinical trial stages, thereby enabling patients to access innovative treatments using cutting-edge technology.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- alphagentx.com/
- Ownership
- Privately Held (backing)
AlphaGen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AlphaGen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AlphaGen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.